Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked conscientiously but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. The first CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set away all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a highly marketing picture in the Uptick Newswire job interview which I came away with an inadequate viewpoint of the business.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the know-how and linked intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) and the first new drug application approval ($five million), and even royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and numerous indications, it’s this individual remedy in addition to a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications and multiple presentations.

Might all of it be smoke and mirrors? That is a question I’ve been asking myself with the very beginning of the interest of mine in this organization. Judging by way of the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or even some could say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *